A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT02249091 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (Relapsed/Refractory)

Interventions

DRUG: Selinexor
DRUG: Idarubicin
DRUG: Cytarabine

Sponsor

GSO Global Clinical Research BV

Collaborators

[object Object]